Abstract
The Zika virus (ZIKV) emerged in Brazil in 2015, causing large outbreaks across South America and the Caribbean. In the years that followed, many countries in these areas reported exceptionally low circulation of Dengue virus (DENV), which later resurged in 2018-2019. Several hypotheses have been proposed to explain low DENV transmission, yet no consensus has been reached so far. We show that while short-term cross-protection induced by ZIKV can explain the temporary disappearance of DENV, it also predicts, in contrast with observations, a rising mean age of DENV incidence in the post-ZIKV era. We further demonstrate that disease enhancement of DENV, especially in primary infections in ZIKV-positive hosts, is required to remedy these shortfalls. Our results suggest that both population-level immunity to DENV and ZIKV contributed positively to the reduction in mean age of DENV incidence.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by the UKRI GCRF One Health Poultry Hub (Grant No. BBS011269/1), one of twelve interdisciplinary research hubs funded under the UK government's Grand Challenge Research Fund Interdisciplinary Research Hub initiative.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Counts of incident Dengue and Zika cases in Feira de Santana used in Figure 1 in the main manuscript were collated from epidemiological bulletins found at Feira de Santana's Secretaria Municipal de Saúde website: https://www.feiradesantana.ba.gov.br/servicos.asp?id=14&link=sms/vigilancia_saude/vigilancia_epidemiologica.asp Age-specific counts of incident Dengue cases and hospitalisations across Brazilian states and the cities of Feira de Santana and Salvador be downloaded from the following repository https://datasus.saude.gov.br/informacoes-de-saude-tabnet/
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced are available online at https://datasus.saude.gov.br/informacoes-de-saude-tabnet/ and https://www.feiradesantana.ba.gov.br/servicos.asp?id=14&link=sms/vigilancia_saude/vigilancia_epidemiologica.asp
https://drive.google.com/file/d/1_K65eUKvG9SituMalYthCcEyuvyhuBis/view?usp=sharing
